Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials
Pooled result · Body weightResult — go to the resultMD −8.20 % 95% CI −10.06 to −6.35Authors' conclusion
Semaglutide 2.4 mg significantly improves weight-related and cardiometabolic outcomes in Asian adults with overweight or obesity. Further studies are warranted to assess long-term effects, real-world applicability and variability across subpopulations.
Study context
- Population
- Asian individuals with overweight or obesity
- Participants
- 2,614 individuals5 randomised controlled trials (RCTs)
- Comparison
- Semaglutide 2.4 mg vs placebo
- Outcome
- Body weight
Methodological detailsmeta-regression, random-effects models, All trials deemed low risk of bias (Cochrane RoB v2)
- Meta-regression
- Random-effects models
- All trials deemed low risk of bias (Cochrane RoB v2)
Pooled result
As reported in the abstract
MD
−8.20 %
95% CI −10.06 to −6.35
Semaglutide 2.4 mgvs Placebo
MD −8.20 % (95% CI −10.06 to −6.35)
Further pooled results
| Outcome | MD (cm) (95% CI) | |
|---|---|---|
| Waist circumferenceI2 = 84% | −6.47 (−8.26 to −4.68) | |
| −10−505Difference, cm (linear scale) |
| Outcome | MD (kg/m²) (95% CI) | |
|---|---|---|
| BMII2 = 66% | −3.22 (−4.01 to −2.44) | |
| −6−4−202Difference, kg/m² (linear scale) |
| Outcome | MD (mmHg) (95% CI) | |
|---|---|---|
| Systolic blood pressureI2 = 28% | −3.46 (−5.29 to −1.62) | |
| −10−505Difference, mmHg (linear scale) |
Weight loss >5%, 10% and 15%
- Higher proportion achieved weight loss >5%, 10% and 15% with semaglutide 2.4 mg
Safety
- GI symptoms most common adverse effects, generally mild to moderate and self-limiting
Original publication
Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials. Diabetes Obes Metab. Published 27 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →